Search research articles
Contact Us
Filters
Showing results (51-60 of 289) with videos related to
Page
of 29
Sort By:
International Journal of Molecular Sciences
|
September 5, 2019
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
Alessandra Raimondi, Giovanni Randon, Pierangela Sepe, et al.
Therapeutic Advances in Medical Oncology
|
September 2, 2016
Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
Elena Verzoni, Paolo Grassi, Raffaele Ratta, et al.
Pharmacology & Therapeutics
|
July 21, 2023
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
Martina Catalano, Giuseppe Procopio, Pierangela Sepe, et al.
Current Drug Targets
|
November 21, 2014
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis
Roberto Iacovelli, Cora N Sternberg, Camillo Porta, et al.
Cancer Treatment Reviews
|
September 7, 2019
Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives
Filippo Pagani, Maurizio Colecchia, Pierangela Sepe, et al.
Anticancer Research
|
April 30, 2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients
Pamela Biondani, Elena Verzoni, Valter Torri, et al.
Future Oncology (London, England)
|
July 24, 2014
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor
Paolo Grassi, Elena Verzoni, Luca Porcu, et al.
British Journal of Clinical Pharmacology
|
August 29, 2013
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy
Roberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, et al.
Targeted Oncology
|
November 22, 2023
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
Brigida Anna Maiorano, Ugo De Giorgi, Elena Verzoni, et al.
Oncology
|
April 18, 2008
Pulmonary carcinoid tumours: indolent but not benign
Sara De Dosso, Emilio Bajetta, Giuseppe Procopio, et al.
Page
of 29
Search research articles
Search
Showing results (51-60 of 289) with videos related to
Sort By:
Page
of 29
International Journal of Molecular Sciences
|
September 5, 2019
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
Alessandra Raimondi, Giovanni Randon, Pierangela Sepe, et al.
Therapeutic Advances in Medical Oncology
|
September 2, 2016
Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
Elena Verzoni, Paolo Grassi, Raffaele Ratta, et al.
Pharmacology & Therapeutics
|
July 21, 2023
Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat?
Martina Catalano, Giuseppe Procopio, Pierangela Sepe, et al.
Current Drug Targets
|
November 21, 2014
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis
Roberto Iacovelli, Cora N Sternberg, Camillo Porta, et al.
Cancer Treatment Reviews
|
September 7, 2019
Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives
Filippo Pagani, Maurizio Colecchia, Pierangela Sepe, et al.
Anticancer Research
|
April 30, 2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients
Pamela Biondani, Elena Verzoni, Valter Torri, et al.
Future Oncology (London, England)
|
July 24, 2014
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor
Paolo Grassi, Elena Verzoni, Luca Porcu, et al.
British Journal of Clinical Pharmacology
|
August 29, 2013
Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy
Roberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, et al.
Targeted Oncology
|
November 22, 2023
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
Brigida Anna Maiorano, Ugo De Giorgi, Elena Verzoni, et al.
Oncology
|
April 18, 2008
Pulmonary carcinoid tumours: indolent but not benign
Sara De Dosso, Emilio Bajetta, Giuseppe Procopio, et al.
Page
of 29